Büller HR - Search Results

1

Clinical impact and course of major bleeding with edoxaban versus vitamin K antagonists.

Brekelmans MP, Bleker SM, Bauersachs R, Boda Z, Büller HR, Choi Y, Gallus A, Grosso MA, Middeldorp S, Oh D, Raskob G, Schwocho L, Cohen AT. Brekelmans MP, et al. Among authors: buller hr. Thromb Haemost. 2016 Jul 4;116(1):155-61. doi: 10.1160/TH15-11-0892. Epub 2016 Mar 24. Thromb Haemost. 2016. PMID: 27010092 Clinical Trial.

2

The incidence of recurrent venous thromboembolism in carriers of factor V Leiden is related to concomitant thrombophilic disorders.

Meinardi JR, Middeldorp S, de Kam PJ, Koopman MM, van Pampus EC, Hamulyák K, Prins MH, Büller HR, van der Meer J. Meinardi JR, et al. Among authors: buller hr. Br J Haematol. 2002 Mar;116(3):625-31. doi: 10.1046/j.0007-1048.2001.03303.x. Br J Haematol. 2002. PMID: 11849222 Free article.

3

A rebuttal: Counseling pregnant women with factor V Leiden homozygosity: use absolute instead of relative risks.

Middeldorp S, van der Meer J, Hamulyák K, Büller HR. Middeldorp S, et al. Among authors: buller hr. Thromb Haemost. 2002 Feb;87(2):360-1; author reply 361. Thromb Haemost. 2002. PMID: 11858509 No abstract available.

4

Treatment of symptomatic venous thromboembolism: improving outcomes.

Büller HR. Büller HR. Semin Thromb Hemost. 2002 Jun;28 Suppl 2:41-8. doi: 10.1055/s-2002-32315. Semin Thromb Hemost. 2002. PMID: 12073179 Review.

5

Recombinant nematode anticoagulant protein c2, a novel inhibitor of tissue factor-factor VIIa activity, abrogates endotoxin-induced coagulation in chimpanzees.

Moons AH, Peters RJ, Cate Ht, Bauer KA, Vlasuk GP, Büller HR, Levi M. Moons AH, et al. Among authors: buller hr. Thromb Haemost. 2002 Oct;88(4):627-31. Thromb Haemost. 2002. PMID: 12362234

6

Co-segregation of thrombophilic disorders in factor V Leiden carriers; the contributions of factor VIII, factor XI, thrombin activatable fibrinolysis inhibitor and lipoprotein(a) to the absolute risk of venous thromboembolism.

Libourel EJ, Bank I, Meinardi JR, Baljé -Volkers CP, Hamulyak K, Middeldorp S, Koopman MM, van Pampus EC, Prins MH, Büller HR, van der Meer J. Libourel EJ, et al. Among authors: buller hr. Haematologica. 2002 Oct;87(10):1068-73. Haematologica. 2002. PMID: 12368162

7

Travel and the risk of symptomatic venous thromboembolism.

ten Wolde M, Kraaijenhagen RA, Schiereck J, Hagen PJ, Mathijssen JJ, Mac Gillavry MR, Koopman MM, Büller HR. ten Wolde M, et al. Among authors: buller hr. Thromb Haemost. 2003 Mar;89(3):499-505. Thromb Haemost. 2003. PMID: 12624634

8

The incidence of recurrent venous thromboembolism after treatment with vitamin K antagonists in relation to time since first event: a meta-analysis.

van Dongen CJ, Vink R, Hutten BA, Büller HR, Prins MH. van Dongen CJ, et al. Among authors: buller hr. Arch Intern Med. 2003 Jun 9;163(11):1285-93. doi: 10.1001/archinte.163.11.1285. Arch Intern Med. 2003. PMID: 12796064

9

Quality of life and the duration of treatment with vitamin K antagonists in patients with deep venous thrombosis.

Locadia M, Sprangers MA, de Haes HC, Büller HR, Prins MH. Locadia M, et al. Among authors: buller hr. Thromb Haemost. 2003 Jul;90(1):101-7. Thromb Haemost. 2003. PMID: 12876632 Clinical Trial.

10

The optimal intensity of vitamin K antagonists in patients with mechanical heart valves: a meta-analysis.

Vink R, Kraaijenhagen RA, Hutten BA, van den Brink RB, de Mol BA, Büller HR, Levi M. Vink R, et al. Among authors: buller hr. J Am Coll Cardiol. 2003 Dec 17;42(12):2042-8. doi: 10.1016/j.jacc.2003.07.029. J Am Coll Cardiol. 2003. PMID: 14680724 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

736 results

Search Page

Filters